FT. Majority of respondents though consider FT to be beneficial in prostate cancer management and would use it more often if provided more reliable and cost effective options. Over time, experience and accessibility to reliable methods to perform FT may lead to further utilization of this novel treatment strategy.
INTRODUCTION AND OBJECTIVES: Earlier work has confirmed the unique thermodynamic properties of phase-change convective radiofrequency (RF) ablation using water vapor (steam) to conform to the anatomical zones of the prostate. The objective of this study was to assess in vivo treatment of prostate cancer and the early clinical effects using convective RF water vapor.
METHODS: A total of 20 patients have been treated at 2 centers using the Reviv System and 6 have completed 6 month follow up biopsy. All patients had clinically localized prostate cancer as determined by biopsy, DRE, PSA and prostate MRI (non mp3). Treatment was performed using a urethral cooling catheter and a transperineal, ultrasound guided approach for needle placement and water vapor delivery. Several doses of thermal energy were tested depending on prostate size. Follow-up monitoring included serial, gadolinium enhanced MRIs performed preprocedure and at 1 week, 1, 3, and 6 months post-procedure and a surveillance biopsy at 6 months post-procedure. Standard AE reporting was used to evaluate clinical outcomes.
RESULTS: 20 patients have been treated. 11 patients underwent hemiablation, 6 whole gland ablation (3 staged), 2 unilateral PZ treatment and 1 hemiablation with contralateral PZ ablation. Serial MRIs confirmed tissue ablation in all patients. Ablation was seen to the prostatic apex, capsular boundaries and the anterior zones of the prostate. Six-month surveillance biopsies have been completed on 6 patients. Four had completely negative biopsies for cancer and two had positive biopsies that were in untreated zones. Catheterization and adverse events will be reviewed. There has been no incontinence, bladder neck contractures or rectal injuries.
CONCLUSIONS: The zonal anatomy of the prostate is ideal for phase change convective RF ablation using water vapor. The thermodynamics and physical principles validated by MRI indicate that effective ablation can be safely delivered anywhere in the prostate including the apex, capsular margins and anterior prostate. Partial, focal, zonal or whole gland ablation can be performed. These early and limited data confirm that effective tissue ablation to all areas of the prostate is feasible using convective thermal water vapor. INTRODUCTION AND OBJECTIVES: Laparoscopic access for RARP is often initiated in the peri-umbilical location. Palmer's Point, located in the left upper quadrant, has been reported as an alternative access site for pelvic laparoscopy to reduce morbidity, but not widely reported among urologists. Furthermore, there are no published articles specifically addressing vascular injuries during RARP access within the literature. To better understand surgeons' preferences for access and its associated morbidity during RARP, we surveyed surgeons from two urological organizations.
METHODS: An anonymous online questionnaire (Survey Monkey) consisting of 17 questions that assessed training, experience, and preferences for RARP was emailed in December 2014 and collected until February 2015 to members performing RARP of the Endourology Society (ES) and the Michigan Urological Society Improvement Collaborative (MUSIC). Surgeons were also asked to share their personal experience with a vascular event or bowel injury during RARP.
RESULTS: Questionnaires were answered by 111 surgeons in total (ES, n¼71 and MUSIC, n¼40) with an estimated total response rate of 5.5% In total, 77% reported prior experience with the Veress needle method before exposure to RARP and 71% of respondents primarily use the Veress needle for RARP, with 73% reporting access primarily at the peri-umbilical location. A personal experience with a vascular or a bowel injury during veress needle insertion was reported in 18% and 9% of surgeons, respectively; furthermore 26% of respondents were personally aware of at least 1 death or life-threatening event among colleagues (5% reported 3 or more). The majority (56%) of respondents were unaware of Palmer's Point, while among the minority aware of Palmer's Point, only 33% reported ever using this location.
CONCLUSIONS: In this survey, surgeons most commonly access the abdomen at the peri-umbilical location with a Veress needle for RARP with the majority not aware or utilizing Palmer's Point. Nearly 1 in 5 surgeons reported a personal experience with a vascular injury and over 1 in 4 reported a death or life-threatning injury among colleagues during access for RARP. Palmer's Point, located away from major vasculature, may reduce the morbidity of access for RARP and warrants further awareness and study, METHODS: We conducted a prospective cohort study of patients undergoing evaluation for asymptomatic microscopic hematuria from January 2009 to July 2016 in an integrated managed care organization in Southern California. Patients' accompanying diagnoses and baseline cohort characteristics were determined and identified using our comprehensive electronic health record system. Cancers indicated in the workup were validated by chart review. Additional cancers documented in the institutional cancer registry through July 2015 were included if diagnosed within 1 year of initial workup. Bivariate associations were assessed using the chi-square test; multivariable logistic e1120 THE JOURNAL OF UROLOGY â Vol. 197, No. 4S, Supplement, Monday, May 15, 2017 
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